Evidence map›Paper›PMID 40355891›Full record

ReviewJournal of translational medicine2025

Protein tyrosine phosphatase receptor type kappa (PTPRK) revisited: evolving insights into structure, function, and pathology.

Chen Zheng, Ting Liu, An Qi Wang, Xing An Chen, Rong Zhe Zhang, Xuan Chao Wang, Chao Yue Lv, Ru Lu Pan, Ou Chen Wang, Xin-Cheng Lu

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chen Zheng *School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Ting Liu *School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
An Qi WangSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Xing An ChenSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Rong Zhe ZhangSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Xuan Chao WangSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Chao Yue LvDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Ru Lu PanSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Ou Chen WangDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Xin-Cheng LuSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, China. xinchenglu@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein Tyrosine Phosphatase Receptor Type Kappa (PTPRK) is a membrane-bound tyrosine phosphatase encoded by the frequently deleted region of chromosome 6q, which plays a crucial role in regulating cell signaling, adhesion, and immune response. Structurally, PTPRK comprises with an extracellular domain involved in cell-cell adhesion, a transmembrane region, and two intracellular catalytic domains responsible for its phosphatase activity. Notably, PTPRK undergoes proteolytic cleavage by Furin and ADAM10, resulting in the generation of an extracellular E-subunit and a P-subunit. Further processing by γ-secretase releases the intracellular PIC, which plays a pivotal role in regulating β-catenin signaling within the nucleus. PTPRK is widely recognized for its tumor-suppressive properties across various cancers, including colorectal, lung, ovarian, and melanoma. Despite its function as a tumor suppressor, the expression and activity of PTPRK exhibit considerable variability across different cancer types and stages. It exerts its effects by dephosphorylating key signaling molecules such as EGFR, STAT3, CD133 and β-catenin, thereby inhibiting cancer cell proliferation, survival, and metastasis. Beyond its role in cancer, PTPRK is also involved in immune regulation, particularly in the development of CD4 + T cells, and has been implicated in autoimmune diseases such as multiple sclerosis. In the nervous system, PTPRK is linked to neurite outgrowth and synaptic transmission, with genetic polymorphisms in PTPRK associated with an increased risk of neurodegenerative diseases like Alzheimer's disease. Given its extensive involvement in cancer biology, immune regulation, and neurodevelopment, PTPRK presents a promising therapeutic target. Strategies aimed at restoring its activity or targeting PTPRK might offer new approaches for current cancer therapies and overcome drug resistance. In this review, we elucidate the structural characteristics and functional roles of PTPRK in cellular signaling and disease pathogenesis. The variability of PTPRK suggests that the regulatory mechanisms governing its activity are intricate and worth further comprehensive investigation.

Indexed as

Receptor-Like Protein Tyrosine Phosphatases, Class 2AnimalsHumansNeoplasmsSignal TransductionStructure-Activity RelationshipReceptor-Like Protein Tyrosine Phosphatases, Class 2

Identifiers

PMID40355891
PMCPMC12067748

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.